Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

M. Azzi



Author of

  • +

    P2.05 - Poster Session with Presenters Present (ID 463)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Radiotherapy
    • Presentations: 1
    • +

      P2.05-052 - A Systematic Review and Meta-Analysis of Pneumonitis in Radically Treated NSCLC Patients: SABR. vs. Non-SABR Treatment (ID 5111)

      14:30 - 14:30  |  Author(s): M. Azzi

      • Abstract

      Background:
      Purpose: SABR is popular because of the high rates of local control seen in lung cancer patients. However, prospective head to head trial data comparing the toxicity of SABR to conventionally fractionated radiotherapy are still awaited. We compare pneumonitis rates in SABR vs. non-SABR treatment for early stage lung cancer patients.

      Methods:
      Methods: A PUBMED search of all human, English language papers on SABR and on-SABR radically treated early stage lung cancer patients was performed until March 2016. The date range for the non-SABR patients extended back to January 1995, but the first 3D-CRT SABR papers assessed were found in 2003. Results of these searches were filtered in accordance to a set of eligibility criteria and analysed in accordance with the PRISMA Guidelines.

      Results:
      Results: The systematic search yielded a total of 184 SABR and 360 non-SABR articles, which were filtered down to 75 SABR and 23 non-SABR articles. SABR patients were older than non-SABR patients with 35/75 SABR papers and 0/23 non-SABR papers recording a median age >75 years. Meta-analysis did not demonstrate a significant difference in pneumonitis rates between patients receiving SABR [11.4% ( 95% CI of 9.7 to 13.3)] and non-SABR treatment [14.4% (95% CI of 10.6 to 18.8)].

      Conclusion:
      Conclusion: Although meta-analysis did not confirm that SABR had lower rates of pneumonitis, it appears that SABR patients are older, and thus potentially frailer than the non-SABR radically treated patients. SABR is safe and has justifiably become the treatment of choice for inoperable patients.